Last C$0.85 CAD
Change Today -0.02 / -2.30%
Volume 80.8K
IMV On Other Exchanges
As of 3:54 PM 04/16/14 All times are local (Market data is delayed by at least 15 minutes).

immunovaccine inc (IMV) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/7/14 - C$1.50
52 Week Low
05/15/13 - C$0.22
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMMUNOVACCINE INC (IMV)

Related News

No related news articles were found.

immunovaccine inc (IMV) Related Businessweek News

No Related Businessweek News Found

immunovaccine inc (IMV) Details

Immunovaccine Inc., a clinical-stage biopharmaceutical company, discovers and develops activators of the immune system to treat cancer and prevent infectious diseases. The company develops its products based on DepoVax vaccine-adjuvanting platform, a vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Its product candidates include DPX-Survivac, a therapeutic cancer vaccine, which has completed Phase I clinical trials for the treatment of ovarian and brain cancer; and DPX-0907, a therapeutic cancer vaccine that has completed Phase I clinical trials for the treatment of breast, ovarian, and prostate cancer. The company also develops pre-clinical stage vaccine product candidates for infectious diseases, including respiratory syncytial virus and anthrax. In addition, its product pipeline consists of DepoVax-validating partnered programs for addiction medicine and animal health. Immunovaccine Inc. was founded in 2000 and is headquartered in Halifax, Canada.

20 Employees
Last Reported Date: 03/14/14
Founded in 2000

immunovaccine inc (IMV) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: C$128.8K
Chief Operating Officer and Director
Total Annual Compensation: C$200.0K
Compensation as of Fiscal Year 2013.

immunovaccine inc (IMV) Key Developments

Immunovaccine's DepoVax(TM) Technology Underpins New Experimental Therapy for Cervical, Head and Neck Cancers

Immunovaccine Inc. announced that its DepoVax(TM) adjuvanting technology will underlie the design of a new cancer vaccine trial that will be conducted by the Dana-Farber Cancer Institute to treat cervical and head and neck cancer. The DepoVax data focused on clinical trial results with DPX-Survivac, which demonstrated strong immune response activity in cancer patients and the immune enhancement observed with the immune modulating agent cyclophosphamide. Dana-Farber's proposed Phase I study in HPV-related cancers will use the same approach, formulating the Institute's peptide-based vaccine in DepoVax and administering it to patients in combination with cyclophosphamide.

Immunovaccine and Pfenex Report Positive Results from Single Dose Anthrax Vaccine Studies

Immunovaccine Inc. and Pfenex Inc. announced positive results from anthrax challenge studies in rabbits using Pfenex's mutant recombinant Protective Antigen (mrPA) formulated with Immunovaccine's DepoVax(TM) delivery system. The studies showed that animals administered a vaccine containing mrPA formulated in DepoVax were protected against a lethal anthrax challenge at a range of antigen doses. DepoVax containing between 0.1 and 9 micrograms of mrPA was tested as a single dose in rabbits to determine the level of neutralizing antibodies produced by the vaccine and its ability to protect against a lethal dose of the anthrax causing bacteria (B. anthracis). All animals vaccinated with a single dose of mrPA - DepoVax containing as little as one third of a microgram of antigen were protected from anthrax infection. Four out of five animals vaccinated with mrPA - DepoVax containing one tenth of a microgram of antigen were also protected. A dose response was observed in the first 28 days following vaccination with higher amounts of mrPA formulated in DepoVax producing higher levels of neutralizing antibodies during this period. In rabbits immunized with a DepoVax vaccine, antibody titers generally plateaued within 28 days and persisted until at least day 70 when animals were exposed to the disease agent. The neutralizing titers measured on day 28 suggest that animals may be protected within one month of a single immunization.

Immunovaccine Inc. Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2013

Immunovaccine Inc. announced audited consolidated earnings results for the year ended December 31, 2013. For the year, the company‘s net loss and comprehensive loss was $4,681,000 for the year ended December 31, 2013 was $1,719,000 lower than the net loss and comprehensive loss during the year ended December 31, 2012. This relates mainly to the $792,000 decrease in research and development (R&D) costs, a $470,000 decrease in accreted interest, an increase in income tax recovery of $205,000, a decrease of $160,000 in general and administration (G&A) expenses, and a decrease of $92,000 in business development (BD) costs.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMV:CN C$0.85 CAD -0.02

IMV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMV.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 25.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOVACCINE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at